| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Lake Street analyst Frank Takkinen initiates coverage on Cellebrite DI (NASDAQ:CLBT) with a Buy rating and announces Price T...
Craig-Hallum analyst Jeff Van Rhee maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $14 to ...
B of A Securities analyst Tal Liani maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $12 to...
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $13 to $13.5.
William Blair analyst Jonathan Ho upgrades Cellebrite DI (NASDAQ:CLBT) from Market Perform to Outperform.
Cellebrite DI Ltd. (NASDAQ:CLBT), a global leader in Digital Investigative solutions for the public and private sectors, today ...
B of A Securities analyst Tomer Zilberman upgrades Cellebrite DI (NASDAQ:CLBT) from Neutral to Buy and announces $12 price t...
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $10 to $13.
Cellebrite DI (NASDAQ:CLBT) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.06 b...
